English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The results of the largest, double-blind, placebo-controlled, multicentre, multinational randomized clinical trial (RCT) evaluating the effects of human growth hormone (hGH) on clinical outcome in 695 haemodialysed adults are published in this issue [1]. Designed to answer the important question whether hGH therapy might improve the notoriously poor survival in patients on dialysis, the OPPORTUNITY trial will enter the collective memory of the nephrology community as a paradigmatic case illustrating the unfortunate dependence of clinical pharmacological research on the short-term interest of industry sponsors.

Missed OPPORTUNITY: growth hormone therapy in adults with CKD